A Phase 3 interventional study of IV Acetaminophen in Acute Pain and Fever, sponsored by Mallinckrodt. Completed at 14 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-10-21.
Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing acetaminophen in Acute Pain — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Acute Pain.
Among the 21 studies testing acetaminophen in Acute Pain, this one is the 9th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 1st registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →1 of the 21 studies testing acetaminophen in Acute Pain is open now, in 1 country. Recruiting first, the newest first:
University of Monastir · Sites in Tunisia
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 102 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 49 (48%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 213 is above the median of 86 across 905 interventional studies indexed under Acute Pain.
Median enrollment 162 across the 21 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
Keenova Therapeutics plc has 7 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing acetaminophen in Acute Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will be investigating safety and efficacy administration of repeated dose of IV Acetaminophen (IV APAP) over five days for the treatment of acute pain or fever in adult patients.
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 g q6h IV Acetaminophen
Drug: IV Acetaminophen
650 mg q4h IV Acetaminophen
Drug: IV Acetaminophen
The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Drug: IV Acetaminophen
Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Also known as: IV Acetaminophen (IV APAP)
Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE).
Number of subjects who experienced at least one treatment emergent adverse event (TEAE). A TEAE is an adverse event that occurs on or after the first dose of study medication (T0).
Time frame: T0 (first dose of IV APAP or randomization to SOC group) to Day 7 - 12 Follow-up
Subjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE)
Serious TEAE is any untoward medical occurrences at any dose of study medication that: * results in death * is life threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event
Time frame: First dose (T0) to within 30 days of the last dose of study medication.
Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments
Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with side effects related to study treatment at End of Day 5 (prior to discharge)
Time frame: End of Day 5 (prior to discharge)
Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.
Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with study treatments looking back over the entire treatment period was conducted at Day 7.
Time frame: Study period lookback at Day 7
Open label study conducted in the US from 21 Feb 2008 -12 Aug 2008
| Milestone | IV Acetaminophen 1 Gram Every 6 Hours | IV Acetaminophen 650 Milligram Every 4 Hours | Standard of Care (SOC) |
|---|---|---|---|
| Started | 92 | 91 | 30 |
| Completed | 65 | 63 | 27 |
| Not completed | 27 | 28 | 3 |
| Withdrew: Adverse event | 11 | 7 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 |
| Withdrew: Protocol non-compliance | 1 | 0 | 0 |
| Withdrew: Early discharge from hospital | 9 | 12 | 3 |
| Withdrew: Subject unable/unwilling to attend visit | 4 | 7 | 0 |
Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with side effects related to study treatment at End of Day 5 (prior to discharge)
| Units on a scale | IV Acetaminophen 1 g q6h | IV Acetaminophen 650 mg q4h | Standard of Care (SOC) |
|---|---|---|---|
| Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments | 2.5 ± 0.78 | 2.5 ± 0.67 | 2.0 ± 0.85 |
Number of subjects who experienced at least one treatment emergent adverse event (TEAE). A TEAE is an adverse event that occurs on or after the first dose of study medication (T0).
| Participants | IV Acetaminophen 1 g q6h | IV Acetaminophen 650 mg q4h | Standard of Care (SOC) |
|---|---|---|---|
| Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE). | 77 | 86 | 26 |
Serious TEAE is any untoward medical occurrences at any dose of study medication that: * results in death * is life threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event
| Participants | IV Acetaminophen 1 g q6h | IV Acetaminophen 650 mg q4h | Standard of Care (SOC) |
|---|---|---|---|
| Subjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE) | 14 | 11 | 3 |
Using a four point categorical scale 0= poor, 1= fair, 2= good, 3= excellent, comparisons of subject's Global Evaluations of the level of satisfaction with study treatments looking back over the entire treatment period was conducted at Day 7.
| Units on a scale | IV Acetaminophen 1 g q6h | IV Acetaminophen 650 mg q4h | Standard of Care (SOC) |
|---|---|---|---|
| Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period. | 2.4 ± 0.75 | 2.3 ± 0.74 | 2.2 ± 0.61 |
Collected over AEs were collected after the start of study medication (T0) until approximately 7 days after the last dose for IVAPAP group or 12 days from T0 for SOC group. SAEs were collected from first dose until 30 days fter the last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Acetaminophen 1 Gram Every 6 Hours | — | 14/92 (15.2%) | 60/92 (65.2%) |
| IV Acetaminophen 650 Milligram Every 4 Hours | — | 11/91 (12.1%) | 68/91 (74.7%) |
| Standard of Care (SOC) | — | 3/30 (10%) | 18/30 (60%) |
| Event | IV Acetaminophen 1 Gram Every 6 Hours | IV Acetaminophen 650 Milligram Every 4 Hours | Standard of Care (SOC) |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/92 | 0/91 | 1/30 |
| Postoperative ileusInjury, poisoning and procedural complications | 0/92 | 1/91 | 1/30 |
| SepsisInfections and infestations | 0/92 | 0/91 | 1/30 |
| Hepatic enzyme increasedInvestigations | 0/92 | 2/91 | 0/30 |
| Postoperative wound infectionInfections and infestations | 2/92 | 2/91 | 0/30 |
| AbscessInfections and infestations | 0/92 | 1/91 | 0/30 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/92 | 1/91 | 0/30 |
| HaematomaVascular disorders | 0/92 | 1/91 | 0/30 |
| Multi-organ failureGeneral disorders | 1/92 | 1/91 | 0/30 |
| Myocardial infarctionCardiac disorders | 1/92 | 1/91 | 0/30 |
| Event | IV Acetaminophen 1 Gram Every 6 Hours | IV Acetaminophen 650 Milligram Every 4 Hours | Standard of Care (SOC) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 23/92 | 34/91 | 8/30 |
| ConstipationGastrointestinal disorders | 18/92 | 21/91 | 5/30 |
| AnaemiaBlood and lymphatic system disorders | 11/92 | 10/91 | 6/30 |
| InsomniaPsychiatric disorders | 13/92 | 17/91 | 5/30 |
| PruritusSkin and subcutaneous tissue disorders | 11/92 | 13/91 | 2/30 |
| HeadacheNervous system disorders | 7/92 | 5/91 | 4/30 |
| VomitingGastrointestinal disorders | 6/92 | 10/91 | 1/30 |
| HypokalaemiaMetabolism and nutrition disorders | 10/92 | 4/91 | 2/30 |
| AnxietyPsychiatric disorders | 4/92 | 2/91 | 3/30 |
| HypotensionVascular disorders | 7/92 | 9/91 | 2/30 |
| Age, Categorical(Participants) | IV Acetaminophen 1g q6h | IV Acetaminophen 650 mg q4h | Standard of Care (SOC) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 48 | 54 | 17 | 119 |
| >=65 years | 44 | 37 | 13 | 94 |
| Sex: Female, Male(Participants) | IV Acetaminophen 1g q6h | IV Acetaminophen 650 mg q4h | Standard of Care (SOC) | Total |
|---|---|---|---|---|
| Female | 49 | 44 | 17 | 110 |
| Male | 43 | 47 | 13 | 103 |
The record gives a start of Jan 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 2 years 1 month after primary completion. A results delay was requested in Apr 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen